Fareva

Fareva is a privately owned French contract development and manufacturing organization whose activities span pharmaceuticals, biologics, cosmetics, home-care products, and selected industrial goods. Founded in 1985 by Bernard Fraisse, the company developed around the outsourcing needs of branded healthcare and consumer-product companies. Rather than primarily selling products under its own consumer-facing name, Fareva works behind the scenes as an industrial partner, supporting activities such as formulation, process development, manufacturing, filling, packaging, and related supply-chain services. The company is headquartered in Tournon-sur-Rhône in the Ardèche department of France. Its industrial footprint includes production facilities in France and other international locations, and its scale has made it one of France's largest contract manufacturing organizations and a significant global participant in pharmaceutical contract manufacturing. Reference material describes a network of approximately 40 production sites and more than 12,500 employees, although these figures are time-sensitive and may change as the group expands or reorganizes. Fareva's business scope is broader than conventional pharmaceutical manufacturing. Its capabilities also cover cosmetics and personal care, home-care products, and industrial formulations. This diversified model allows the company to serve customers across regulated healthcare markets and faster-moving consumer categories, while using shared expertise in formulation, quality systems, production engineering, packaging, and regulatory compliance. A major strategic development came in 2020, when Fareva acquired two biologics-related facilities from Pierre Fabre. The transaction added an oncology injectable plant in Pau, in southwestern France, and a monoclonal-antibody production facility in Saint-Julien-en-Genevois near the French-Swiss border. The acquisition strengthened Fareva's presence in higher-complexity pharmaceutical manufacturing and expanded its capabilities in sterile and biologic production. Fareva remains privately held and is associated with Bernard Fraisse, who founded the business and is identified in reference material as its 100 percent owner. Because the company is private, publicly available information about detailed financial performance, management changes, customer contracts, and site-level operations is limited. Its competitive positioning is based on breadth of capabilities, manufacturing scale, technical expertise, and the ability to provide integrated services to international healthcare and consumer-product brands.

Fareva was founded in 1985 by Bernard Fraisse in France. Its development followed the growth of outsourced manufacturing in healthcare and consumer products, as brand owners increasingly sought specialized partners for formulation, industrial production, packaging, and quality-controlled supply-chain operations. Fareva built its business as a contract manufacturer rather than as a mass-market brand, allowing it to work for multiple pharmaceutical, cosmetics, home-care, and industrial customers. Over time, the company expanded its manufacturing network and broadened its technical scope. Pharmaceutical production became a central part of its identity, while cosmetics, personal care, home care, and industrial products provided additional areas of activity. This combination positioned Fareva as a diversified industrial services provider capable of handling both regulated healthcare products and high-volume consumer formulations. By the period covered in the available reference material, Fareva had become one of the largest contract manufacturing organizations in France and one of the leading pharmaceutical contract manufacturers globally. The company was described as operating more than 40 production sites and employing over 12,500 people. Its international footprint enabled it to support customers across multiple markets, although the precise number and location of operating sites can change over time and should be verified against current company disclosures. The most clearly documented expansion in the available sources occurred in 2020. Fareva acquired two facilities previously owned by Pierre Fabre: an oncology injectable manufacturing plant in Pau, in southwestern France, and a monoclonal-antibody facility in Saint-Julien-en-Genevois, close to the Swiss border. The transaction increased Fareva's exposure to sterile injectable production and biologics, both of which require specialized equipment, stringent quality systems, and advanced technical capabilities. Fareva is headquartered in Tournon-sur-Rhône, in France's Ardèche department. It remains privately owned and is identified with Bernard Fraisse, its founder and owner. Public information about the group's detailed corporate structure, financial results, customer portfolio, and executive team is comparatively limited because it is not a listed company. The available record nevertheless presents Fareva as a substantial French-based contract manufacturing group whose principal competitive strengths are scale, manufacturing diversification, technical specialization, and the ability to provide integrated services to international brands.

• 2020

  Expansion into biologics and oncology manufacturing

  [1]Farevaen.wikipedia.org

  Fareva acquired two Pierre Fabre facilities: an oncology injectable plant in Pau and a monoclonal-antibody production site in Saint-Julien-en-Genevois.

• 1985

  Fareva is founded

  [1]Farevaen.wikipedia.org

  Bernard Fraisse founded Fareva in France, establishing the privately owned business that would develop into a diversified contract manufacturing group.

A large, vertically capable contract manufacturer providing development and production services across pharmaceuticals, biologics, cosmetics, home care, and industrial products.

• Pharmaceutical services

  Pharmaceutical contract manufacturing

  Fareva manufactures pharmaceutical products for third-party customers and supports associated development, formulation, production, filling, packaging, and quality activities. Its role is primarily industrial and business-to-business: the finished products are generally marketed by client companies rather than sold to consumers under the Fareva name.

• Biopharmaceutical manufacturing · 2020

  Biologics and monoclonal antibodies

  Following the 2020 acquisition of Pierre Fabre facilities, Fareva added a monoclonal-antibody production site to its manufacturing network. The activity gives the group a presence in biologics manufacturing, an area requiring specialized processes, contamination control, analytical testing, and rigorous regulatory quality systems.

• Sterile pharmaceutical manufacturing · 2020

  Oncology injectables

  Fareva's Pau facility produces oncology injectables, extending the group's capabilities into sterile and complex pharmaceutical products. Such operations typically involve controlled environments, specialized filling processes, and stringent quality requirements, although the available reference material does not specify individual products or client brands.

• Consumer-product contract manufacturing

  Cosmetics and personal-care products

  Fareva provides contract development and manufacturing services for cosmetics and personal-care products. Its capabilities are described as including formulation and production, with packaging and related services available as part of an integrated offering for brand owners.

• Specialty formulation manufacturing

  Home-care and industrial products

  Beyond healthcare and beauty, Fareva manufactures selected home-care and industrial formulations. These activities diversify the group across consumer and industrial applications and make use of its broader expertise in formulation, production, packaging, and operational scale.

• 2020

  Acquisition of Pierre Fabre biologics facilitiesM&A

  Background

  Fareva sought to expand its pharmaceutical manufacturing platform into biologics and complex sterile products.

  Action taken

  The company acquired Pierre Fabre's oncology injectable plant in Pau and monoclonal-antibody production facility in Saint-Julien-en-Genevois.

  Aftermath

  The transaction broadened Fareva's capabilities in oncology injectables, biologics, and monoclonal-antibody manufacturing.

  Source

1. 1Farevaen.wikipedia.org
2. 2Fareva official websitefareva.com